1Joel M,Nentel MD,Martin P,et al.Efficacy of valsartan in patients aged≥65yesrs with systolic hypertension.Clin Ther,2000,22:961.
2Pdzzeni D,Porteri E,Boafi GE.Prognogtic significance of small artery structure in hypertension.Circulation,2003,108:2230.
3Savoia C,Touyz RM,Endermann DH.Angiotension receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.Hypertension,2006,48:27l.
4Pfeffer MA,Mcmurray JJY,Velazquez EJ,et al.Valsartan,captopril,or both in myocardial infarction complicated by heart failure,left ventricular dysfunction,or both.N Engl J Med,2003,349(20):1893.
5Cohn JN,Tognoni G.Valsartan Heart Failure Trial Investigators.A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure.N Engl J Med,2001,345(23):1667.
6Ridker PM,Danielson E,Rifai N.Valsartan,blood pressure reduction,and Creactive protein:primary report of the Val-MARC Trial.Hypertension,2006,48:73.
7Serebmany VL,Pokov AN,Malinin AI.Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives:Valsartan Inhibits Platelets (VIP)trial.Am Heart J,2006,151:92.
8Kjeldsen SE,Julius S,Mancia G.Effects of valsartan of valsartan to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients:the VALUE triaI.J Hypertens,2006,24:1405.
9Viberti G,Wheeldon NM.Microalbuminuria reduction with valsartan in patients with type2 diabetes mellitus:blood pressure independent effect.Circulatioll,2002,106:672.
10Owens P,Kelly L.Comprasion of antihypertensive and metabolic effects 0f vaIsartan and valsartan in combination with hydrochlorothiazide a randomized controlled triai.J Hypertens,2000,18:339.
二级参考文献7
1Calhoun ME,Juck M,Martin LJ,et al.Comparative evaluation of synaptophys in based methods for quantification of synapses [J].J Neurocyt,1996,25:821-828.
2Wright JW,Reichert JR,Davis CJ,et al.Neural plasticity and the brain rennin-angiotensin system [J].Neurosci Biobehav Rev,2002,26(5):529-525.
3Kusaka I,Kusaka G,Zhou C,et al.Role of AT1 receptors and NAD (P)H oxidase in diabetes-aggravated ischemic brain injury [J].Physiol Heart Circ Physiol.2004,286(6):2442-2451.
4Jing G,Grammatopoulos T,Ferguson P.Inhibitory effects of angiotensin on NMDA-induced cytotoxicity in primary neuronal cultures[J].Brain Res Bull,2004,62(5):397-403.
7Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney dis- ease in China: a cross,sectional survey [J]. Lancet, 2012, 379 (9818):815 - 822.
8Chen G, McAlister FA, Walker RL, et al. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure[J]. Hypertension,2011, 57 (5):891 - 897.
9Genuth S. The UKPDS and its global impact[J]. Diabet Med, 2008, 25(Suppl 2):57-62.
10Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: ob- servations from traditional and bayesian random-effects meta- analyses of randomized trials [J]. Circulation, 2011,123 (24):2799 2I0.
